Home/Pipeline/Islet Cell Transplantation for T1D

Islet Cell Transplantation for T1D

Type 1 Diabetes

Pre-clinicalActive

Key Facts

Indication

Type 1 Diabetes

Phase

Pre-clinical

Status

Active

Company

ViCapsys

About ViCapsys

ViCapsys is a private, pre-revenue biotech leveraging a platform based on the cytokine CXCL12 to locally modulate immune and inflammatory responses. Its lead program aims to enable long-term survival of transplanted pancreatic islet cells to cure Type 1 Diabetes, with supporting data from non-human primate studies. The company is also developing non-cellular applications for diabetic foot ulcers and abdominal adhesions, building on intellectual property licensed from Massachusetts General Hospital.

View full company profile

Therapeutic Areas

Type 1 Diabetes Diabetic Foot Ulcers Abdominal Adhesions

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
eRapa	Biodexa Pharmaceuticals	Preclinical	Research
ImmCelz™	Creative Medical Technology Holdings	Clinical Trial	Active
Adimune (ADi-001/002)	Aditxt	Preclinical / Early Clinical	Active
MSC‑Diabetes	Advancells	Phase 1	Active
BioChaperone® Lispro (THDB0206)	Adocia	Phase 3	Active
AdoShell® Islet Cell Therapy	Adocia	Preclinical	Platform Development
Pediatric Indications (<2 years)	Tandem Diabetes	Research	Exploratory
Icovamenib (BMF-219)	Biomea Fusion	Phase 2	Completed Follow-up, Data Pending
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research
Sotagliflozin	Lexicon Pharmaceuticals	Phase 3	Regulatory Path Uncertain
Stem Cell-Derived Beta Cells	BioTalentum	Pre-clinical	Active
NICHE	Continuity Biosciences	Pre-clinical	Active